2026-2034年全球勃起功能障碍治疗市场规模、份额、趋势和成长分析报告

预计到 2034 年，治疗勃起功能障碍的市场规模将从 2025 年的 41.1 亿美元增长至 90.4 亿美元，2026 年至 2034 年的复合年增长率为 9.14%。

受文明病增加的推动，全球勃起功能障碍治疗市场正稳定成长。人们对男性健康问题的日益关注，加速了全球相关治疗的普及。人口老化导致男性人口不断增长，也显着促进了市场需求的扩大。学名药的普及提高了治疗的可近性和可负担性。这些因素共同推动了市场的持续成长。

主要促成因素包括糖尿病、高血压和心血管疾病盛行率的上升。压力大的生活方式和久坐的习惯正在增加勃起功能障碍的发生率。线上药局和远端医疗平台正在改善药物取得途径。製药公司正在投资研发副作用较少的改良配方。开发中国家医疗保健覆盖范围的扩大进一步刺激了需求。

鑑于对先进治疗方法的持续研究，前景依然乐观。研发出药效更持久、疗效更佳的药物将带来成长机会。社会对疗法的接受度提高将有助于提升其普及率。新兴市场蕴藏着巨大的未开发潜力。药物输送系统的持续创新将塑造未来的市场扩张。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球勃起功能障碍治疗市场：依药物类型划分

• 市场分析、洞察与预测
• Sildenafil
• 他达拉非
• 伐地那非
• 阿伐那菲尔
• 其他的

第五章 全球勃起功能障碍治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服锭剂
• 注射药物
• 外用药物

第六章 全球勃起功能障碍治疗市场：依最终使用者划分

• 市场分析、洞察与预测
• 医院
• 诊所
• 居家照护

第七章 全球勃起功能障碍治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Teva Pharmaceutical Industries Ltd
  • SK Chemicals Co. Ltd
  • Cristalia Produtos QuAfA-Micos FarmacAfAªUticos Ltd
  • Futura Medical Plc
  • GlaxoSmithKline PLC
  • Petros Pharmaceuticals
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Cipla Ltd
  • Endo International Plc

The Erectile Dysfunction Drugs Market size is expected to reach USD 9.04 Billion in 2034 from USD 4.11 Billion (2025) growing at a CAGR of 9.14% during 2026-2034.

The global erectile dysfunction drugs market is growing steadily due to increasing prevalence of lifestyle-related disorders. Rising awareness about men's health issues is encouraging treatment adoption worldwide. The growing aging male population significantly contributes to demand growth. Availability of generic alternatives has improved affordability and accessibility. These factors collectively drive consistent market expansion.

Key drivers include rising cases of diabetes, hypertension, and cardiovascular diseases. Stressful lifestyles and sedentary habits are increasing the incidence of erectile dysfunction. Online pharmacies and telehealth platforms are improving drug accessibility. Pharmaceutical companies are investing in improved formulations with fewer side effects. Expanding healthcare access in developing countries is further supporting demand.

Future prospects remain favorable with ongoing research into advanced treatment options. Development of longer-lasting and more effective medications offers growth opportunities. Increased social acceptance of treatment will support higher adoption rates. Emerging markets present significant untapped potential for manufacturers. Continuous innovation in drug delivery systems will shape future market expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others

By Mode of Administration

• Oral Tablets
• Injectables
• Topical Medications

By End User

• Hospitals
• Clinics
• Homecare

COMPANIES PROFILED

• Teva Pharmaceutical Industries Ltd, SK Chemicals Co Ltd, Cristalia Produtos Qumicos Farmacuticos Ltd, Futura Medical plc, GlaxoSmithKline PLC, Petros Pharmaceuticals, Lupin Limited, Glenmark Pharmaceuticals Limited, Cipla Ltd, Endo International plc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Sildenafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Tadalafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vardenafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Avanafil Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY MODE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Mode Of Administration
• 5.2. Oral Tablets Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectables Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Medications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Type
  • 7.2.2 By Mode Of Administration
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Type
  • 7.3.2 By Mode Of Administration
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Type
  • 7.4.2 By Mode Of Administration
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Type
  • 7.5.2 By Mode Of Administration
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Type
  • 7.6.2 By Mode Of Administration
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ERECTILE DYSFUNCTION DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Teva Pharmaceutical Industries Ltd
  • 9.2.2 S.K. Chemicals Co. Ltd
  • 9.2.3 Cristalia Produtos QuAfA-Micos FarmacAfAªUticos Ltd
  • 9.2.4 Futura Medical Plc
  • 9.2.5 GlaxoSmithKline PLC
  • 9.2.6 Petros Pharmaceuticals
  • 9.2.7 Lupin Limited
  • 9.2.8 Glenmark Pharmaceuticals Limited
  • 9.2.9 Cipla Ltd
  • 9.2.10 Endo International Plc